Ikena Oncology, Inc.
Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form D; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.
Raised
Pre-open
Investors
—
Min Invest
None stated
Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.
What this filing shows
·Every sentence is a value as filed on SEC Form D
Ikena Oncology, Inc. is a Delaware corporation that filed a Form D with the SEC on July 18, 2025 in the Biotechnology industry group. The offering claims Rule 506(b) and covers equity. Ikena Oncology, Inc. reported that the first sale had not yet occurred as of the Form D filed July 18, 2025, so no amount sold or investor count is on file. The total offering amount is $75,000,000. The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated. The Form D names LEERINK PARTNERS LLC (CRD 39011), associated with None as the recipient of sales compensation soliciting in all states. Sales commissions are reported as $0 and finders' fees as $0. Form D allows these to be estimates. The issuer's address of record is 12526 High Bluff Drive, San Diego, CA 92130.
EDGAR Filing Data
Form D — Primary Source
View on SEC.govFilings on Record
Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.
In the Terminal
Filing events
1
latest Jul 18, 2025
Critical / warning
0 / 0
0 watch · 1 info
Statements extracted
0
none on file
NAV prints
0
none on file
Offering chains
2
pre_sale, closed
Latest event New filer · Jul 18, 2025
SEC.govInvestor
- 1 filing event with values and deltas, latest 2025-07-18, and alerts on the next one
- 2 offering timelines: velocity, share raised, first-sale lag, stalled flags
Pro
- This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
- The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV
Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…
Related Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
Item 3 changed on the Form D filed 2025-07-18: 0 related persons added and 2 removed against the filing of 2023-08-18; 10 now listed. The names are in the Terminal feed.
Mark Manfredi
Executive Officer, Director · Boston, MA
Jotin Marango
Executive Officer · Boston, MA
Jeffrey Ecsedy
Executive Officer · Boston, MA
David Bonita
Director · Boston, MA
Iain Dukes
Director · Boston, MA
Jean-Francois Formela
Director · Boston, MA
Otello Stampacchia
Director · Boston, MA
Maria Koehler
Director · Boston, MA
Richard Wooster
Director · Boston, MA
Owen Hughes
Director · Boston, MA
Placement Agents and Sales Compensation (Form D)
Who the issuer reported paying to sell the securities (Form D Item 12), with the FINRA registration number the filer gave. Source: SEC.gov.
LEERINK PARTNERS LLCCRD 39011 on BrokerCheck
Associated broker-dealer: None · BOSTON, MA · Soliciting in all states
Questions About Ikena Oncology, Inc.
Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.
What is Ikena Oncology, Inc.?
Ikena Oncology, Inc. is a Delaware corporation that filed a Form D with the SEC on July 18, 2025 in the Biotechnology industry group. The filing claims Rule 506(b) for an offering of equity.
Is Ikena Oncology, Inc. legit?
AltStreet does not rate legitimacy; it reports the public record. Ikena Oncology, Inc. filed a Form D with the SEC on July 18, 2025 claiming Rule 506(b). A Form D is a notice of an exempt offering, not a review or approval of it. No sales had been reported as of that notice. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.
Is Ikena Oncology, Inc. registered with or approved by the SEC?
No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that Ikena Oncology, Inc. claimed Rule 506(b) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.
How much has Ikena Oncology, Inc. raised?
Ikena Oncology, Inc. reported that the first sale had not yet occurred as of the Form D filed July 18, 2025, so no amount sold or investor count is on file. The total offering amount is $75,000,000.
Who can invest in Ikena Oncology, Inc.?
The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated.
What is the minimum investment in Ikena Oncology, Inc.?
The Form D lists the minimum investment as $0, which means the issuer did not state a minimum on the form. The offering documents, not the Form D, set the actual subscription terms.
Who is selling Ikena Oncology, Inc. and how are they paid?
The Form D names LEERINK PARTNERS LLC (CRD 39011), associated with None as the recipient of sales compensation soliciting in all states. Sales commissions are reported as $0 and finders' fees as $0. Form D allows these to be estimates.
Who is behind Ikena Oncology, Inc.?
The Form D lists 10 related persons: Mark Manfredi, executive officer, director; Jotin Marango, executive officer; Jeffrey Ecsedy, executive officer; David Bonita, director; Iain Dukes, director; Jean-Francois Formela, director; Otello Stampacchia, director; Maria Koehler, director, and 2 more. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.
Where is Ikena Oncology, Inc. located?
The issuer's address on its SEC filings is 12526 High Bluff Drive, San Diego, CA 92130. Its phone number of record is 857-343-8292. It is organized under the laws of Delaware.
How long is the Ikena Oncology, Inc. offering open?
The issuer indicated that the offering is not intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open, and no amendment is on record yet.
What is Ikena Oncology, Inc.'s revenue?
The issuer declined to disclose its revenue range on the Form D, which the form permits.
Is this your company or fund?
Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.
Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.